**The role of multispecies social interactions in shaping *Pseudomonas aeruginosa* pathogenicity in the cystic fibrosis lung**

Siobhán O’Brien1, 2 & Joanne L Fothergill3

1Center for Adaptation to a Changing Environment (ACE), ETH Zürich, 8092 Zürich,  
Switzerland

siobhan.obrien@env.ethz.ch

2Department of Biology, University of York, Wentworth Way, York, UK, YO10 5DD

3Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, Liverpool, UK, L69 7B3

**Abstract**

*P. aeruginosa* is a major pathogen in the lungs of cystic fibrosis (CF) patients. However, it is now recognised that a diverse microbial community exists in the airways comprising of aerobic and anaerobic bacteria as well as fungi and viruses. This rich soup of microorganisms provides ample opportunity for interspecies interactions, particularly when considering secreted compounds. Here, we discuss how *P. aeruginsoa* secreted products can have community-wide effects, with the potential to ultimately shape microbial community dynamics within the lung. We focus on three well-studied traits associated with worsening clinical outcome in CF: phenazines, siderophores and biofilm formation, and discuss how secretions can shape interactions between *P. aeruginosa* and other commonly encountered members of the lung microbiome: *Staphylococcus aureus*, the *Burkholderia cepacia* complex, *Candida albicans* and *Aspergillus fumigatus.* These interactions may shape the evolutionary trajectory of *P. aeruginosa*, ultimately providing new opportunities for therapeutic exploitation of the CF lung microbiome.

Keywords: Interspecific interactions, Multispecies interactions, Microbiome, Cystic Fibrosis, *Pseudomonas aeruginosa*, Microbial communities

**Introduction**

Individuals with cystic fibrosis (CF) suffer from a buildup of thick, viscous mucous in the airways, predisposing them to lifelong bacterial lung infections which are often fatal. *Pseudomonas aeruginosa* is the most common pathogen in CF, displaying high levels of antibiotic resistance and virulence – so that elimination is apparently impossible (Pressler et al 2011). Chronic infection with *P. aeruginosa* is associated with deterioration of pulmonary function, reduction in quality of life and premature death (Koch & Hoiby, 1993; Emerson et al 2002; Hart & Winstanley 2002).

The CF lung airways consist of polymicrobial infections that vary in their composition and diversity throughout a patient’s lifetime. Diversity typically increases during the first decade of life, and decreases thereafter (Cox et al 2010; Klepac-Ceraj 2010). While *Haemophilus influenzae* and *Staphylococcus aureus* are present mainly in young children, by the age of 20, 60–70% of CF-patients present intermittent colonization by *P. aeruginosa* (Folkesson et al 2012). Earlier acquisition of *P. aeruginosa* has been associated with a more rapid decline in lung function and poorer clinical outcomes (Emerson et al 2002). In at least 50% of adult CF patients, *P. aeruginosa* has been reported as the dominant organism, displacing the resident microbial community (Valenza et al 2008). Furthermore, CF patients infected with *P. aeruginosa* are vulnerable to developing secondaryinfections, for example with *Burkholderia cepacia* complex, predisposing patients to necrotizing pneumonia, which is usually fatal (Sajjan et al 2001; Bragonzi et al 2012). Fungi and yeasts also inhabit the airways, where *Aspergillus fumigatus* and *Candida albicans* are the most prevalent fungi and yeast, respectively (Chotirmall & McElvaney 2014). Although their prevalence is likely underestimated and detection methods vary between diagnostic laboratories, both *Aspergillus sp* and *Candida sp* have been identified in up to 50% of CF patients (Chotirmall et al 2010, Pihet et al 2009).

The recent surge in the number of studies employing in-depth, parallel, next generation sequencing of CF lung microbial communities has given a greater insight into what exactly lives in this complex ecosystem. Inhabiting microorganisms range from recognized pathogens such as *Pseudomonas sp* and *Burkholderia sp* to bacteria less understood in the context of CF such as *Prevotella sp* and *Veillonella sp* **(**Fodor et al 2012; Boutin et al 2015), and classically commensal microorganisms such as oral Streptococci. A novel isolation method led to the detection of *Candida dubliniensis* in patients >30 years with advanced stages of the disease, although the importance of this fungal pathogen in CF is not yet understood (Sahand et al 2005; Chortimall et al 2010). Lower respiratory tract microbiome studies have also supported the identification of new proposed pathogens in the CF lung such as *Ralstonia mannitolilytica*, identified in seven patients in Canada and associated with accelerated disease progression and raised mortality (Coman et al 2017). In addition to identifying novel bacterial species, metagenomic studies have revealed a diverse viral community in the CF lung with over 450 viral genotypes identified (Lim et al 2014). Furthermore, some of these viruses have been linked to the onset of pulomonary exacerbations (periods of acute worsening of pulmonary symptoms) (Billard et al 2017).

Lung microbial diversity tends to decrease with increasing disease severity (as *P. aeruginosa* dominates the population) (Cox et al 2010; Fodor et al 2012; Frayman et al 2017). However, whether this association is linked to increased *P. aeruginosa* pathogenicity remains elusive. Lung community diversity can be highly patient specific and no universal indicator of the onset of exacerbation has been identified so far (Whelan et al 2017). Furthermore, during antibiotic treatment, limited changes in microbial community structure have been identified (Fodor et al 2012; Li et al 2016).

Through our progressive understanding of the complexities of polymicrobial communities, it is becoming increasingly clear that interactions between bacterial pathogens and the microbial community within which they reside can influence pathogenesis, antimicrobial resistance and disease progression (Hoffman et al 2006; Peters et al 2012; Antonic et al 2013; Baldan et al 2014; Fugère et al 2014; Beaume et al 2015). However, it is often difficult to elucidate whether these clinical changes are a cause or consequence of these interactions. In this review, we highlight the role of multispecies interactions in shaping *P. aeruginosa* virulence, and discuss examples where these interactions may be of paramount importance in predicting patient health. Secreted products by *P. aeruginosa* are likely to influence neighbouring microorganisms, and it is reasonable to suggest that community context may in turn shape the relative costs and benefits associated with these secretions. Crucially, this implies that the role of some CF microorganisms in disease may be subtle, acting through cross-species interactions rather than being recognised pathogens *per se.*

**How might multispecies interactions shape *P. aeruginosa* virulence?**

Over the course of chronic infections*, P. aeruginosa* CF isolates commonly display adaptive phenotypes such as conversion to mucoidy and loss of motility, as well as reduced expression of acute virulence factors and extracellular toxins (Smith et al 2006; Bragonzi et al 2009; Folkesson et al 2012; Lorè et al 2012; Davies et al 2016; Winstanley et al 2016). Despite the general trend toward loss of virulence as *P. aeruginosa* becomes chronic, it is becoming increasingly clear that loss of virulence is not universal within a patient. Furthermore, *P. aeruginosa* isolates within patients are typically highly diverse with respect to the aforementioned phenotypic characteristics (Fothergill et al 2010; Mowat et al 2011; O’Brien et al 2017). Despite the potential for *P. aeruginosa* adaptive evolution to influence patient health, both the causes and consequences of these adaptive changes are not well understood. The ability of many microbial secretions to influence the fitness of other organisms either directly (e.g. bacteriocin mediated killing) or indirectly (e.g. antibiotic degradation), with potential for positive (cooperation) or negative (competition) fitness consequences, suggests that microbial interactions may play an integral role in shaping *P. aeruginosa* evolution within the CF lung.

Here, we focus on four clinically relevant *P. aeruginosa* traits that may in part, shape, and be shaped by interactions with the natural microbial community. Crucially, these traits have potential to be ‘social’ – that is, they may directly or indirectly influence the fitness of nearby cells (West et al 2007). This list is not exhaustive, but should be regarded as examples of microbial traits whose role cannot be fully understood without consideration of community context.

1. *Phenazine production*

Phenazines are secondary metabolites produced by a variety of bacteria, notable for their broad-spectrum antibiotic properties and roles in virulence (Sorensen & Klinger 1987). Phenazine production is mediated by quorum sensing (QS), a method of bacterial cell-cell communication which allows the coordinated expression of genes in bacterial populations (Dietrich et al 2006). *P. aeruginosa* secretes four main classes of phenazines: pyocyanin, phenazine-1-carboxamide (PCN), 1-hydroxyphenazine (1-HP) and phenazine-1-carboxylic acid (PCA) (Figure 1). One class of phenazine, pyocyanin, is a blue redox-active pigment that exerts a host inflammatory response, impairs ciliary function and induces oxidative stress within the lung (O’Malley et al 2003; Winstanley & Fothergill 2009). While the effects of pyocyanin on the host may influence other microorganisms indirectly, there is some evidence that pyocyanin can also have a direct role in shaping microbial communities. Pyocyanin can function as an iron-reducing agent, allowing iron-limited microorganisms to thrive (see below) (Cox 1986). Furthermore, the bactericidal effect of pyocyanin may reduce community diversity (Norman et al 2004) and select for a community of resistant species. Two recent studies (Korgaonkar & Whiteley 2011; Korgaonka et al 2013) reported that *P. aeruginosa* responds directly to cell wall fragments from Gram-positive bacteria by increasing production of multiple extracellular factors, including pyocyanin. Co-infection of *P. aeruginosa* with avirulent Gram-positive bacteria in both rat lung and *Drosophila* models, resulted in increased lung damage and overall enhanced virulence respectively (Duan et al 2003; Korgaonka et al 2013), although the exact mechanisms are unknown. Clinical isolates respond similarly: Whiley et al (2014) reported enhanced *P. aeruginosa* pyocyanin production when co-cultured with oral viridans streptococci (*Streptococcus oralis*, *Streptococcus mitis*, *Streptococcus gordonii* and *Streptococcus sanguinis),* and these co-cultures exhibited increased pathogenicity in an insect host model compared with *P. aeruginosa* alone. However, in this case increased pathogenicity might also have arisen from other virulence associated secretions, rather than pyocyanin per se.

Studies in which animal models are infected with *P. aeruginosa* strains producing varying levels of pyocyanin reveal that pyocyanin production tends to lead to more virulent infections (Mahajan-Miklos et al 1999; Cao et al 2001; Lau et al 2004a,b; Courtney et al 2007; O’Brien et al 2017). In CF, periods of patient exacerbations have been linked with increased pyocyanin production in the lung (Fothergill et al 2007; Fothergill et al 2010; Mowat et al 2011). However, not all patients with worsening symptoms harbor increased numbers of overproducing phenotypes (Nguyen and Singh 2006; Smith et al 2006), and the causality of this relationship remains unconvincing. Furthermore, why pyocyanin over-producers evolve and thrive in some scenarios and not others remains to be elucidated. Interestingly, while virulence is predictably lost over the course of CF infections, longitudinal studies of pyocyanin production have so far failed to detect any predictable evolutionary changes over the course of chronic infections (Jiricny et al 2014; Winstanley et al 2016). We speculate that multispecies interactions can at least partly explain the observed fluctuations in pyocyanin production. If this is the case, assays for pyocyanin production by clinical isolates in media or even artificial sputum models that mimic abiotic conditions in the CF lung (e.g. Jiricny et al 2014; Fothergill et al 2010; Mowat et al 2011; O’Brien et al 2017) may not be sufficient indicators of what these strains are producing *in vivo*. Ultimately, by understanding whether community context matters for *P. aeruginosa* pyocyanin production, it may be possible to manipulate the lung microbiome to reduce the severity of clinical symptoms during CF-associated exacerbations.

*b) Biofilm formation*

The intractability of *P. aeruginosa* in CF has been largely attributed to the presence of mucoid alginate-producing strains in the later stages of infection (Ramsey & Wozniak, 2005; Sousa & Periera 2014; Winstanley et al 2016). These strains form resilient biofilms, conferring enhanced resistance to antibiotics, phage, and the host immune system, ultimately causing a decline in lung function (Høiby et al 2010a,b). While this transition to mucoidy is commonly viewed as a global response to environmental stress (e.g Davies et al 2016), there is some evidence that multispecies social interactions may play a role. For instance, ethanol produced by *C. albicans* stimulates biofilm formation in *P. aeruginosa* (DeVault et al 1990), while a protein secreted by *S. aureus*, SpA, inhibits it (Armbruster et al 2016) (Figure 2). Exopolysachharides can also impact on spatial organization in polymicrobial biofilms (Chew et al 2014). One *P. aeruginosa* exopolysaccharide, Pel, is required for a close association in biofilms with *S. aureus*. However, another exopolysaccharide, Psl, allows *P. aeruginosa* to form a single species biofilm on top of *S. aureus.* Therefore, the type of exopolysaccharide produced by *P. aeruginosa* can impact the architecture of the biofilm and the ability of these two species to interact closely (Chew et al 2014).

Viruses of bacteria (phages) have also been described in the CF lung (Lim et al 2013), and are a promising novel way of eliminating drug resistant pathogens (Waters et al 2017). Interactions between *P. aeruginosa* and lytic phages (which lyse the bacterial cell upon infection) may drive the transition to mucoidy by enhancing resistance to phage infection (Miller & Rubero, 1984; Scanlan & Buckling 2011). Conversely, evolving *P. aeruginosa* with temperate phages (which can either complete the lytic cycle or integrate into the bacterial chromosome as a prophage), can reduce biofilm formation by accelerating the loss of biofilm-dependent type IV pili (Klausen et al 2003, Davies et al 2016). While understanding how the abiotic and biotic environment interact to promote mucoidy is no easy task- it is an endeavor worth exploring. Mucoid variants of *P. aeruginosa* are highly problematic in the clinic, and novel therapeutics aimed at disrupting mucoidy are highly valuable (Romling & Balsalobre 2012; Gnanadhas et al 2015).

*c) Iron-acquisition*

Iron is an essential nutrient for many microorganisms, yet in the early stages of CF lung infection the availability of iron for inhabiting microbiota is highly restricted (Tyrrell & Callaghan 2016). *P. aeruginosa* can overcome this by producing iron-chelating siderophores that can acquire otherwise sequestered ferric iron. Due to their capacity to enhance bacterial growth, siderophores are viewed as virulence factors (Buckling et al 2007). A wide body of research suggests that iron uptake strategy in Pseudomonads can be influenced by social context, because non-producers can exploit producers, and gain a fitness advantage(e.g. Griffin et al 2004; Harrison et al 2005,2007; O’Brien et al 2013; Andersen et al 2015*).* However, most of these studies are limited to intraspecific interactions in spatially homogenous environments (but see Luján et al 2015).

In the CF lung, many species compete for iron simultaneously, and this competition can indirectly shape iron-uptake strategies in *P. aeruginosa*. For instance, competition between *P. aeruginosa* and *B. cepacia* induces *P. aeruginosa* genes normally expressed under iron-limited conditions (including siderophores). This is because a *B. cepacia* siderophore, ornibactin (which *P. aeruginosa* cannot use) restricts iron availability to *P. aeruginosa* (Weaver & Kolter 2004). A similar phenomenon was observed using experimental evolution, whereby *P. aeruginosa* was evolved in the presence and absence of *S. aureus* (Harrison et al 2008). In this case, *P. aeruginosa* upregulated siderophore production in response to *S. aureus*, which acted as an iron competitor. Conversely, *P. aeruginosa* can obtain iron by lysing *S. aureus* cells (Mashburn et al 2005), although Harrison et al (2008) suggest that this benefit depends on the degree of competition between the two strains. Interestingly, when multiple species compete for iron, subsequent iron-limitation may also reduce the ability of *P. aeruginosa* to form biofilms (Singh et al 2002; O’May et al 2009). This is in line with what we observe in longitudinal studies of CF isolates, whereby iron becomes more available, and biofilms become more common over the course of infection (Hunter et al 2013; Tyrrell and Callaghan 2016; Winstanley et al 2016). However, this correlation can be of course open to different interpretations.

There is some evidence to suggest that the requirement for siderophores is reduced in the later stages of infection, as freely available ferrous (Fe2+) tends to dominate over ferric iron (Hunter et al 2013). Furthermore, as host cells are damaged they release iron in the form of haem and haemoglobin, from which *P. aeruginosa* can sequester iron using the haem assimilation system (Has) and Phu (Pseudomonas haem uptake) systems. Indeed, over the course of chronic infections there is some evidence that siderophores are lost and replaced with haem utilization (Marvig et al 2014). Finally, the role of pyocyanin in iron-acquisition per se is poorly understood, although one study suggests that a different phenazine, PCA, assists in biofilm development by promoting ferrous iron (Wang et al 2011). Crucially, the role of various iron-uptake systems in shaping microbial communities may differ depending on the predominant form of acquisition. While siderophore sharing is generally species-specific (Buckling et al 2007, but see Barber and Elde 2015), other acquisition mechanisms such as pyocyanin-mediated reduction is unlikely to be limited to conspecifics, and so understanding how they might be shaped by community interactions is not straightforward.

**Case studies**

While the scope for interactions within the CF lung is clearly vast, we highlight interactions between *P. aeruginosa* and four commonly encountered species: the Gram-positive bacteria *S. aureus*; the *B. cepacia* complex (Gram-negative); a filamentous fungi (*A. fumigatus*) and *C. albicans* (a yeast) to display the breadth and diversity of interactions with *P. aeruginosa*.

*a) P. aeruginosa and S. aureus*

*P. aeruginosa* and *S. aureus* display a striking negative correlation with one another as CF patients age (Cystic Fibrosis Foundation 2011), suggesting that *P. aeruginosa* can displace *S. aureus* in the later stages of infection*.* *P. aeruginosa* secretes a wealth of *S. aureus* killing exoproducts, such as pyocyanin, elastase, protease, rhamnolipids, 4-hydroxy-2-alkylquinoline (HAQ), and 4-hydroxy-2-heptylquinoline-*N*-oxide (HQNO) (Mashburn et al 2005; Palmer et al 2005; Hoffman et al 2006; Mitchell et al 2010; Korgaonkar & Whiteley 2011; Cardozo et al 2013; Korgaonkar et al 2013; DeLeon et al 2014). *P. aeruginosa* can also harm *S. aureus* indirectly by manipulating the innate immunity of the host, such as inducing the production of *S. aureus*-killing phospholipase sPLA2-IIA by bronchial epithelial cells (Pernet et al 2014). This interaction between the host and *P. aeruginosa* enhances the clearance of *S. aureus*, without significantly affecting the growth of *P. aeruginosa*. It is of course debatable whether the upregulation of sPLA2-IIA by *P. aeruginosa* has evolved as a competitor-killing mechanism, or if it simply a response by the host to which *P. aeruginosa* is resistant. Nonetheless, sPLA2-IIA is the most potent known antibacterial enzyme in mammals, especially targeting Gram-positive bacteria, suggesting that interactions between *P. aeruginosa* andthe hostcan shape bacterial communities more widely (Nevalainen et al 2008; Qu & Lehrer 1998). Finally, one recent study that experimentally evolved *P. aeruginosa* in the presence and absence of *S. aureus*, demonstrated that adaptation to *S. aureus* was mediated by inactivation of virulence-associated lipopolysaccharide (LPS) in *P. aeruginosa.* Crucially, this adaptation also conferred enhanced resistance to beta-lactam antibiotics, despite that evolution took place in their absence (Tognon et al 2017).

Crucially, any counter adaptation by *S. aureus* to resist killing by *P. aeruginosa* can in turn shape the pathogenicity of *S. aureus*. Small colony variants of *S. aureus* (SCVs) arise by mutations in metabolic genes (Melter & Radojevic 2010), and experience reduced killing by *P. aeruginosa* HQNO’s compared to their wild-type counterparts (Hoffman et al 2006; Biswas et al 2009; Filkins et al 2015). From a clinical perspective, SCVs display enhanced resistance to antibiotics (Wolter et al 1995), greater persistence (Hoffman et al 2006) and correlate with worsening symptoms in CF (Wolter et al 2013). Moreover, HQNO has been identified in CF patients harbouring *P. aeruginosa*, but not in uninfected individuals, suggesting that HQNO-mediated interactions between these two species have potential to directly influence disease progression (Hoffman et al 2006).

*b) P. aeruginosa and Aspergillus fumigatus*

*A. fumigatus* is the most common fungus found in the CF airways (Nagano et al 2007; Pihet et al 2009), and its presence is associated with a diversity of clinical phenotypes ranging from no obvious respiratory decline, to *Aspergillus* bronchitis and bronchiectasis (Shoseyov et al 2006; Agarwal et al 2013; Chotirmally & McElavaney 2014). Infection tends to occur subsequent to *P. aeruginosa* colonisation, resulting in co-infections that trigger more severe clinical outcomes compared with *P. aeruginosa or A. fumigatus* alone (Amin et al 2010; Ferreira et al 2015; Reece et al 2017).

Several lines of evidence suggest that these two species interact extensively in the CF lung. *P. aeruginosa* has been classically viewed as inhibiting *A. fumigatus* growth by producing an array of phenazines which kill fungi at high concentrations (Kerr et al 1994; Moree et al 2012; Briard et al 2015). However, in the CF lung, the phenazines pyocyanin and phenazine-1-carboxylate have been found *in vivo* at concentrations in the range of 1 to 100 µM, which Briard et al (2015) demonstrated to be subinhibitory against *A. fumigatus*. Furthermore, at these concentrations, these phenazines actually function as iron-reducing agents, liberating bioavailable iron and subsequently, fungal growth in iron-starved environments. Another phenazine, 1-HP, stimulates siderophore production in *A. fumigatus* and growth as a consequence. Accordingly, there is a generally high percentage of Fe2+ once phenazine levels rise above 50 µM in sputum (Hunter et al 2012, 2013). However, concentrations of phenazines may in reality vary within the lung, particularly in the lower respiratory tract where mucous is more concentrated. These findings may explain why *A. fumigatus* infections tend to occur after *P. aeruginosa* colonization – *P. aeruginosa* creates an iron-rich environment in which *A. fumigatus* can thrive. However, an alternative explanation is that co-infection reduces the pro-inflammatory response exerted by the host, potentially enabling both strains to thrive (Reece et al 2017). Furthermore, damaged lungs *per se* permit better colonization by pathogens and increased virulence as a consequence.

*c) P. aeruginosa and Candida albicans*

Despite being the 2nd most common fungus in CF, the role of *C. albicans* in CF is not fully understood. In practice, this means that a positive result for *C. albicans* in the clinic tells us little about patient prognosis. While invasive airway infections by *C. albicans* alone remain rare, its pathogenic effects may be experienced through interactions with other species. For instance, in mixed biofilms with *C. albicans,* *P. aeruginosa* upregulates its production of virulence associated secretions such as pyoverdine, phenazines and rhamnolipids, relative to single species biofilms (Hogan & Kolter 2002; Hogan et al 2004; Cugini et al 2007; Gibson et al 2009; Trejo-Hernández et al 2014). Enhanced phenazine production by *P. aeruginosa* in turn upregulates *C. albicans* ethanol production, as the phenazines exert a switch from respiration to fermentation (Morales et al 2013). As mentioned previously, ethanol increases *P. aeruginosa* biofilm formation, resulting in mucoid phenotypes with enhanced growth rate (DeVault et al 1990; Morales et al 2013) (Figure 2). This phenazine-mediated switch to fermentation in *C. albicans* may have consequences for microbiome diversity and composition. Ethanol has also been shown to enhance growth, virulence and biofilm formation in other lung pathogens such as *S. aureus* (Korem et al 2010) and *Acinetobacter baumanii* (Nwugo et al 2012) although the exact mechanisms have not yet been elucidated. Ethanol is also an immunosuppressant, negatively influencing the host immune response (Greenberg et al 1999; Goral et al 2008). In a rat model system, ethanol inhibits lung clearance of *P. aeruginosa* by inhibiting macrophage recruitment (Greenberg et al 1999). Hence, ethanol may indirectly shape microbial communities by interfering with pathogen clearance. Another fermentation product, acetic acid, is also likely to reduce extracellular pH, which may favour the presence of low-pH adapted microorganisms (Morales et al 2013).

Signalling can occur between these two species, influencing one another’s gene expression and virulence. The *P. aeruginosa* signal molecule 3-oxo-C12HSL promotes the yeast form of *C. albicans* – so that when levels of this signal drop (such as during chronic infection (Bjarnsholt et al 2010)), the invasive, filamentous form of the fungus may be triggered (McAlester et al 2008). Conversely, *C. albicans* secrete the alcohol farnesol that suppresses the *P. aeruginosa* signal molecule PQS and consequently, pyocyanin production, while inducing quinolone and phenazine expression (Cugini et al 2007; 2010). Finally, *C. albicans* can reduce the expression of the siderophores pyoverdine and pyochelin in *P. aeruginosa* leading to decreased virulence (Lopez-Medina et al 2015), although exact mechanisms have yet to be elucidated. Clearly, these interactions, and their effects on gene expression, are complex, and we are far from understanding how they will combine to influence host health.

*d) P. aeruginosa and B. cepacia complex*

Secondary bacterial infections with *B cepacia complex* are associated with cepacia syndrome - a rapidly progressing and fatal pneumonia (Huang et al 2001; Lambiase et al 2006). Members of the *B. cepacia* complex form mucoid biofilms with *P. aeruginosa*, engaging in an intimate network of interactions, and possibly even exchanging genetic material (Eberl & Tummler 2004).

Competition between these two species is rife. In one study that screened 66 *P. aeruginosa* and *B. cenocepacia* CF clinical isolates, 81% of *P. aeruginsoa* and 57% of *B. cenocepacia* strains produced bacteriocin-like toxins, conferring inhibitory activity toward the other species (Bakkal et al 2010). Populations of *Burkholderia* have been found to invade populations of *P. aeruginosa* (Schwab et al 2014) and vice versa (Bragonzi et al 2012; Costello et al 2014), suggesting that the outcome of competition is highly context dependent. Interactions between these two species may also occur in more subtle ways: one class of signal molecules produced by *P. aeruginos*a, N-acyl homoserine lactones, can stimulate the production of siderophores, lipase, and protease production production in *Burkholderia* (Mc Kenny et al 1995; Riedel et al 2001; Lewenza et al 2002; Costello et al 2014). Moreover, alginate production by *P. aeruginosa* can aid *B. cenocepacia* survival by inhibiting the host immune response (Chattoraj et al 2010). Despite the role of both species as harmful pathogens, how their interactions may influence virulence is not well understood.

There has been a recent drive toward developing novel therapeutics using products secreted by naturally occurring competitors to target specific pathogens in not just CF (e.g. Brown et al 2009) but halitosis (Burton et al 2006) and *Clostridium difficile* (Rea et al 2013) infections. In particular, one *Burkholderia* bacteriocin named Tailocin has been proposed as a potential therapeutic with activity against *P. aeruginosa* (Yao et al 2017). In order to fully appreciate how *P. aeruginosa* populations will respond to these classes of drugs it is vital that we understand how the species involved interact naturally on both ecological and evolutionary timescales.

**Outlook**

There is tantalising evidence that interactions within and among species can alter virulence properties of *P. aeruginosa* in the short term and potentially shape the evolutionary trajectory of this pathogen in the long term. While our knowledge of how *P. aeruginosa* responds to other species individually is growing, the consequences of these interactions for virulence in a complex multispecies community remains unclear. Moreover, experimental evolution studies in complex environments containing the natural microbiota are required to decipher whether ecological responses drive selection for evolutionary change. On the one hand, multispecies infections may constrain the rate of evolutionary change if trade-offs are required to adapt to multiple species. On the other hand, increasing the number of interacting species may result in even more rapid evolution, as selection acts on increasing numbers of traits.

Understanding how virulence -associated secretions are shaped by the lung microbiome opens doors for novel therapeutic approaches already being exploited in gut microbiome research (Bakken et al 2011, Hamilton et al 2012, Lee et al 2016). For instance, an increased understanding of community dynamics could allow us to establish “infection resistant” communities to prevent initial colonization of recognized pathogens or by replacing pathogens with commensal communities. This approach has already proved successful in treating *Clostridium difficile* gut infections with “healthy” gut communities (Bakken et al 2011, Hamilton et al 2012, Lee et al 2016), and *Streptococcus mutans* dental caries with lactobacillus communities (Gungor et al 2015). Furthermore, through an increased understanding of the ecology of these lung communities, it may be possible to suppress *P. aeruginosa* indirectly by manipulating clinically relevant interactions.

However, there are many challenges. As a field, we are not clear on what a “normal” or “healthy” community might look like against a genetic background of CF. Furthermore, spatial structure in the lung, at both molecular and geographical scales, will impact the ability of colonising species to interact. However, the relevance of this structure for cell-cell interactions, as well as the extent to which sputum samples capture this structure is unknown. Finally, the vast genotypic and phenotypic variation observed in *P. aeruginosa* populations from the same sputum sample (Mowat et al 2011; O’Brien et al 2017) suggests that in order to fully understand and characterize these fascinating populations, interactions should be considered on both a species and strain level. Clearly this is a hugely overwhelming task, but employing novel model systems that incorporate natural or semi-natural microbial communities, allow us to make small steps toward achieving this goal (e.g. Harrison et al 2014).

**Funding**

S.O.B. was supported by the Wellcome Trust (ref: 105624) through the Centre for Chronic Diseases and Disorders (C2D2) at the University of York, and is currently supported by an Adapting to Changing Environments (ACE) research fellowship at ETH Zürich. J.L.F would like to acknowledge support from the Leverhulme Trust and the Medical Research Foundation.

**References**

Agarwal R, Chakrabarti A, Shah A, *et al.* Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy, 2013;**43**:850-873

Amin R, Dupuis A, Aaron SD *et al.* The Effect of Chronic Infection With *Aspergillus fumigatus* on Lung Function and Hospitalization in Cystic Fibrosis Patients. *Chest* 2010;**137**:171–6.

Andersen SB, Marvig RL, Molin S *et al.* Long-term social dynamics drive loss of function in pathogenic bacteria. *Proc Natl Acad Sci U S A* 2015;**112**:10756–61.

Antonic V, Stojadinovic A, Zhang B *et al.* *Pseudomonas aeruginosa* induces pigment production and enhances virulence in a white phenotypic variant of *Staphylococcus aureus*. *Infect Drug Resist* 2013;**6**:175–86.

Armbruster CR, Wolter DJ, Mishra M *et al.* *Staphylococcus aureus* Protein A Mediates Interspecies Interactions at the Cell Surface of *Pseudomonas aeruginosa*. *mBio* 2016;**7**:1–9.

Bakkal S, Robinson SM, Ordonez CL *et al.* Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients. *Microbiology* 2010;**156**:2058–67.

Bakken JS, Borody T, Brandt LJ *et al.* Treating clostridium difficile infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol* 2011;**9**:1044–9.

Baldan R, Cigana C, Testa F *et al.* Adaptation of *Pseudomonas aeruginosa* in cystic fibrosis airways influences virulence of *Staphylococcus aureus in vitro* and murine models of co-infection. *PLoS One* 2014;**9**:e89614.

Barber MF, Elde NC. Buried Treasure: Evolutionary Perspectives on Microbial Iron Piracy. *Trends Genet* 2015;**31**:627–36.

Beaume M, Köhler T, Fontana T *et al.* Metabolic pathways of *Pseudomonas aeruginosa* involved in competition with respiratory bacterial pathogens. *Front Microbiol* 2015;**6**:1–12.

# [Billard L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Billard%2520L%255BAuthor%255D&cauthor=true&cauthor_uid=28340310), [Le Berre R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Le%2520Berre%2520R%255BAuthor%255D&cauthor=true&cauthor_uid=28340310), [Pilorgé L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pilorg%25C3%25A9%2520L%255BAuthor%255D&cauthor=true&cauthor_uid=28340310), et al. Viruses in cystic fibrosis patients' airways. [Crit Rev Microbiol.](https://www.ncbi.nlm.nih.gov/pubmed/28340310) 2017: 1-19.

Biswas L, Biswas R, Schlag M *et al.* Small-Colony Variant Selection as a Survival Strategy for *Staphylococcus aureus* in the Presence of *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 2009;**75**:6910–2.

Bjarnsholt T, Jensen PØ, Jakobsen TH *et al.* Quorum sensing and virulence of *Pseudomonas aeruginosa* during lung infection of cystic fibrosis patients. *PLoS One* 2010;**5**, DOI: 10.1371/journal.pone.0010115.

Boutin S, Graeber SY, Weitnauer M *et al.* Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis. *PLoS One* 2015;**10**:e0116029.

Bragonzi A, Farulla I, Paroni M *et al.* Modelling Co-Infection of the Cystic Fibrosis Lung by *Pseudomonas aeruginosa* and *Burkholderia cenocepacia* Reveals Influences on Biofilm Formation and Host Response. *PLoS One* 2012;**7:** e52330.

Bragonzi A, Paroni M, Nonis A *et al.* *Pseudomonas aeruginosa* microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. *Am J Respir Crit Care Med* 2009;**180**:138–45.

Briard B, Bomme P, Lechner BE *et al.* *Pseudomonas aeruginosa* manipulates redox and iron homeostasis of its microbiota partner Aspergillus fumigatus via phenazines. *Sci Rep* 2015;**5**:13

Brown SP, West SA, Diggle SP *et al.* Social evolution in micro-organisms and a Trojan horse approach to medical intervention strategies. *Philos Trans R Soc Lond B Biol Sci* 2009;**364**:3157–68.

Buckling A, Harrison F, Vos M *et al.* Siderophore-mediated cooperation and virulence in *Pseudomonas aeruginosa*. *FEMS Microbiol Ecol* 2007;**62**:135–41.

Burton JP, Chilcott CN, Moore CJ *et al.* A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters. *J Appl Microbiol* 2006;**100**:754–64.

Cao H, Baldini RL & Rahme LG. Common mechanisms for pathogens of plants and animals. *Annu Rev Phytopathol*  2001; **39**: 259–284

Cardozo VF, Oliveira AG, Nishio EK *et al.* Antibacterial activity of extracellular compounds produced by a *Pseudomonas* strain against methicillin-resistant *Staphylococcus aureus* (MRSA) strains. *Ann Clin Microbiol Antimicrob* 2013;**12**:12.

Chattoraj SS, Murthy R, Ganesan S *et al.* *Pseudomonas aeruginosa* alginate promotes *Burkholderia cenocepacia* persistence in cystic fibrosis transmembrane conductance regulator knockout mice. *Infect Immun* 2010;**78**:984–93.

Chew SC huen, Kundukad B, Seviour T *et al.* Dynamic remodeling of microbial biofilms by functionally distinct exopolysaccharides. *MBio* 2014;**5**:e01536–14.

Chotirmall SH, O’Donoghue E, Bennett K et al. Sputum *Candida albicans* presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010; **138**:1186-1195.

Chotirmall SH, McElavaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? *Int J Biochem Cell Biol,* 2014; **52**:161-173

Coman I, Bilodeau L, Lavoie A *et al.* *Ralstonia mannitolilytica* in cystic fibrosis: A new predictor of worse outcomes. *Respir Med Case Reports* 2017;**20**:48–50.

Costello A, Reen FJ, O’Gara F *et al.* Inhibition of co-colonizing cystic fibrosis-associated pathogens by *Pseudomonas aeruginosa* and *Burkholderia multivorans*. *Microbiology* 2014;**160**:1474–87.

Courtney JM, Bradley J, Mccaughan J *et al.* Predictors of mortality in adults with cystic fibrosis. *Pediatr Pulmonol* 2007;**42**:525–32.

Cox CD. Role of pyocyanin in the acquisition of iron from transferrin. *Infect Immun* 1986;**52**:263–70.

Cox MJ, Allgaier M, Taylor B *et al.* Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. *PLoS One* 2010;**5**: e11044.

Cugini C, Calfee MW, Farrow JM *et al.* Farnesol, a common sesquiterpene, inhibits PQS production in *Pseudomonas aeruginosa*. *Mol Microbiol* 2007;**65**:896–906.

Cugini C, Morales DK, Hogan DA. Candida albicans-produced farnesol stimulates Pseudomonas quinolone signal production in LasR-defective *Pseudomonas aeruginosa* strains. *Microbiology* 2010;**156**:3096–107.

Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2010 Annual Report, 2011.

Davies E V, James CE, Williams D *et al.* Temperate phages both mediate and drive adaptive evolution in pathogen biofilms. *Proc Natl Acad Sci U S A* 2016;**113**:8266–71.

DeLeon S, Clinton A, Fowler H *et al.* Synergistic interactions of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in an in vitro wound model. *Infect Immun* 2014;**82**:4718–28.

DeVault JD, Kimbara K, Chakrabarty AM. Pulmonary dehydration and infection in cystic fibrosis: evidence that ethanol activates alginate gene expression and induction of mucoidy in *Pseudomonas aeruginosa*. *Mol Microbiol* 1990;**4**:737–45.

# [Dietrich LE](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dietrich%2520LE%255BAuthor%255D&cauthor=true&cauthor_uid=16879411), [Price-Whelan A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Price-Whelan%2520A%255BAuthor%255D&cauthor=true&cauthor_uid=16879411), [Petersen A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Petersen%2520A%255BAuthor%255D&cauthor=true&cauthor_uid=16879411), *et al*. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of *Pseudomonas aeruginosa*. [Mol Microbiol.](https://www.ncbi.nlm.nih.gov/pubmed/?term=dietrich+2006+pyocyanin) 2006 ;61:1308-21.

Duan K, Dammel C, Stein J *et al.* Modulation of *Pseudomonas aeruginosa* gene expression by host microflora through interspecies communication. *Mol Microbiol* 2003;**50**:1477–91.

Eberl L, Tümmler B. *Pseudomonas aeruginosa* and *Burkholderia cepacia* in cystic fibrosis: Genome evolution, interactions and adaptation. *Int J Med Microbiol* 2004;**294**:123–31.

Emerson J, Rosenfeld M, McNamara S *et al.* *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol* 2002;**34**:91–100.

Ferreira JAG, Penner JC, Moss RB, *et al*. Inhibition of *Aspergillus fumigatus* and its biofilm by *Pseudomonas aeruginosa* is dependent on the source, phenotype and growth conditions of the bacterium. *PloS One* 2015;**10**: e0134692

Filkins LM, Graber JA, Olson DG *et al.* Coculture of *Staphylococcus aureus* with *Pseudomonas aeruginosa* Drives *S. aureus* towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model. *J Bacteriol* 2015;**197**:2252–64.

Fodor AA, Klem ER, Gilpin DF *et al.* The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. *PLoS One* 2012;**7**:e45001.

Folkesson A, Jelsbak L, Yang L *et al.* Adaptation of *Pseudomonas aeruginosa* to the cystic fibrosis airway: an evolutionary perspective. *Nat Rev Microbiol* 2012;**10**:841–51.

Fothergill JL, Mowat E, Ledson MJ *et al.* Fluctuations in phenotypes and genotypes within populations of *Pseudomonas aeruginosa* in the cystic fibrosis lung during pulmonary exacerbations. *J Med Microbiol* 2010;**59**:472–81.

Fothergill JL, Panagea S, Hart CA *et al.* Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. *BMC Microbiol* 2007;**7**:45.

Frayman KB, Armstrong DS, Carzino R *et al.* The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. *Thorax* 2017;**0:**1-9

Fugère A, Séguin DL, Mitchell G *et al.* Interspecific small molecule interactions between clinical isolates of *Pseudomonas aeruginosa* and *Staphylococcus aureus* from adult cystic fibrosis patients. *PLoS One* 2014;**9:** e86705.

Gibson J, Sood A, Hogan DA. *Pseudomonas aeruginosa*-*Candida albicans* Interactions: Localization and Fungal Toxicity of a Phenazine Derivative . *Appl Environ Microbiol* 2009;**75**:504–13.

Gnanadhas DP, Elango M, Datey A *et al.* Chronic lung infection by *Pseudomonas aeruginosa* biofilm is cured by L-Methionine in combination with antibiotic therapy. *Sci Rep* 2015;**5**:16043.

Goral J, Karavitis J, Kovacs EJ. Exposure-dependent effects of ethanol on the innate immune system. *Alcohol* 2008;**42**:237–47.

Greenberg SS, Zhao X, Hua L *et al.* Ethanol inhibits lung clearance of *Pseudomonas aeruginosa* by a neutrophil and nitric oxide-dependent mechanism, in vivo. *Alcohol Clin Exp Res* 1999;**23**:735–44.

Griffin AS, West S a, Buckling A. Cooperation and competition in pathogenic bacteria. *Nature* 2004;**430**:1024–7.

Gungor OE, Kirzioglu Z, Kivanc M. Probiotics:can they be used to improve oral health? *Benef Microbes* 2015. **6**(5):647-56.

Hamilton MJ, Weingarden AR, Sadowsky MJ *et al.* Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. *Am J Gastroenterol* 2012;**107**:761–7.

Harrison F, Buckling A. Hypermutability impedes cooperation in pathogenic bacteria. *Curr Biol* 2005;**15**:1968–71.

Harrison F, Buckling A. High relatedness selects against hypermutability in bacterial metapopulations. *Proc Biol Sci* 2007;**274**:1341–7.

Harrison F, Paul J, Massey RC *et al.* Interspecific competition and siderophore-mediated cooperation in *Pseudomonas aeruginosa*. *ISME J* 2008;**2**:49–55.

Harrison F, Muruli A, Higgins S *et al.* Development of an ex vivo porcine lung model for studying growth, virulence and signaling of *Pseudomonas aeruginosa*. *Infect Immun* 2014;**82**:3312–23.

Hart CA, Winstanley C. Persistent and aggressive bacteria in the lungs of cystic fibrosis children. *Br Med Bull* 2002;**61**:81–96.

Hoffman LR, Deziel E, D’Argenio DA *et al.* Selection for *Staphylococcus aureus* small-colony variants due to growth in the presence of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 2006;**103**:19890–5.

Hogan DA, Kolter R. *Pseudomonas-Candida* interactions: an ecological role for virulence factors. *Science* 2002;**296**:2229–32.

Hogan DA, Vik Å̊, Kolter R. A *Pseudomonas aeruginosa* quorum-sensing molecule influences Candida albicans morphology. *Mol Microbiol* 2004;**54**:1212–23.

Høiby N, Bjarnsholt T, Givskov M *et al.* Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents* 2010a;**35**:322–32.

Hoiby N, Ciofu O, Bjarnsholt T. *Pseudomonas aeruginosa* biofilms in cystic fibrosis. *Future Microbiol* 2010b;**5**:1663–74.

Huang CH, Jang TN, Liu CY *et al.* Characteristics of patients with *Burkholderia cepacia* bacteremia. *J Microbiol Immunol Infect* 2001;**34**:215–9.

Hunter RC, Asfour F, Dingemans J *et al.* Ferrous iron is a significant component of bioavailable iron in cystic fibrosis airways. *MBio* 2013;**4**: e00557-13

Hunter RC, Klepac-Ceraj V, Lorenzi MM *et al.* Phenazine content in the cystic fibrosis respiratory tract negatively correlates  with lung function and microbial complexity. *Am J Respir Cell Mol Biol* 2012;**47**:738–45.

Jiricny N, Molin S, Foster K *et al.* Loss of social behaviours in populations of *Pseudomonas aeruginosa* infecting lungs of patients with cystic fibrosis. *PLoS One* 2014;**9**: e83124

Kerr J. Inhibition of fungal growth by *Pseudomonas aeruginosa* and *Pseudomonas cepacia* isolated from patients with cystic fibrosis. *J Infect* 1994;**28**:305–10.

Klepac-Ceraj V, Lemon KP, Martin TR *et al.* Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and *Pseudomonas aeruginosa*. *Environ Microbiol* 2010;**12**:1293–303.

Koch C, Hoiby N. Pathogenesis of cystic fibrosis. *Lancet (London, England)* 1993;**341**:1065–9.

Korem M, Gov Y, Rosenberg M. Global gene expression in *Staphylococcus aureus* following exposure to alcohol. *Microb Pathog* 2010;**48**:74–84.

Korgaonkar AK, Whiteley M. *Pseudomonas aeruginosa* enhances production of an antimicrobial in response to N-acetylglucosamine and peptidoglycan. *J Bacteriol* 2011;**193**:909–17.

Korgaonkar A, Trivedi U, Rumbaugh KP *et al.* Community surveillance enhances *Pseudomonas aeruginosa* virulence during polymicrobial infection. *Proc Natl Acad Sci* 2013;**110**:1059–64.

Lambiase A, Raia V, Del Pezzo M *et al.* Microbiology of airway disease in a cohort of patients with cystic fibrosis. *BMC Infect Dis* 2006;**6**:4.

Lau GW, Hassett DJ, Ran H *et al.* The role of pyocyanin in *Pseudomonas aeruginosa* infection. *Trends Mol Med* 2004;**10**:599–606.

Lau GW, Ran H, Kong F *et al. Pseudomonas aeruginosa* pyocyanin is critical for lung infection in mice. *Infect. Immun.,* 72 (2004), pp. 4275–4278

Lee CH, Steiner T, Petrof EO *et al.* Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *Jama* 2016;**315**:142–9.

Lewenza S, Visser MB, Sokol P a. Interspecies communication between *Burkholderia cepacia* and *Pseudomonas aeruginosa*. *Can J Microbiol* 2002;**48**:707–16.

Li J, Hao C, Ren L *et al.* Data Mining of Lung Microbiota in Cystic Fibrosis Patients. *PLoS One* 2016;**11**:e0164510.

Lim YW, Schmieder R, Haynes M, *et al*. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. *J Cyst Fibros*. 2013;**12**(2):154–164.

Lim YW, Evangelista JS, Schmieder R *et al*. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. *J Clin Microbiol* 2014; **52**:563-9.

Lopez-Medina E, Fan D, Coughlin LA *et al.* *Candida albicans* Inhibits *Pseudomonas aeruginosa* Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis. *PLoS Pathog* 2015;**11**: e1005129.

Lorè NI, Cigana C, De Fino I *et al.* Cystic Fibrosis-Niche Adaptation of *Pseudomonas aeruginosa* Reduces Virulence in Multiple Infection Hosts. *PLoS One* 2012;**7**:e35648.

Lujan AM, Gomez P, Buckling A. Siderophore cooperation of the bacterium *Pseudomonas fluorescens* in soil. *Biol Lett* 2015;**11**:20140934–20140934.

Mahajan-Miklos S, Tan MW, Rahme LG*et al*. Molecular mechanisms of bacterial virulence elucidated using a *Pseudomonas aeruginosa*-*Caenorhabditis elegans*pathogenesis model. *Cell*  1999 **96**: 47–56.

Marvig RL, Damkiær S, Hossein Khademi SM *et al.* Within-host evolution of *Pseudomonas aeruginosa* reveals adaptation toward iron acquisition from hemoglobin. *MBio* 2014;**5**, DOI: 10.1128/mBio.00966-14.

Mashburn LM, Jett AM, Akins DR *et al.* *Staphylococcus aureus* serves as an iron source for *Pseudomonas aeruginosa* during *in vivo* coculture. *J Bacteriol* 2005;**187**:554–66.

# [Melter O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Melter%2520O%255BAuthor%255D&cauthor=true&cauthor_uid=21253898), [Radojevič B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Radojevi%25C4%258D%2520B%255BAuthor%255D&cauthor=true&cauthor_uid=21253898). Small colony variants of *Staphylococcus aureus*--review. [Folia Microbiol (Praha).](https://www.ncbi.nlm.nih.gov/pubmed/21253898) 2010;55:548-58.

McAlester G, O’Gara F, Morrissey JP. Signal-mediated interactions between *Pseudomonas aeruginosa* and *Candida albicans*. *J Med Microbiol* 2008;**57**:563–9.

McKenney D, Brown KE, Allison DG. Influence of *Pseudomonas aeruginosa* exoproducts on virulence factor production in *Burkholderia cepacia*: evidence of interspecies communication. *J Bacteriol* 1995;**177**:6989–92.

Miller R V, Rubero VJ. Mucoid conversion by phages of *Pseudomonas aeruginosa* strains from patients with  cystic fibrosis. *J Clin Microbiol* 1984;**19**:717–9.

Mitchell G, Séguin D, Asselin A-E *et al.* *Staphylococcus aureus* sigma B-dependent emergence of small-colony variants and biofilm production following exposure to *Pseudomonas aeruginosa* 4-hydroxy-2-heptylquinoline-N-oxide. *BMC Microbiol* 2010;**10**:33.

Morales DK, Grahl N, Okegbe C *et al.* Control of *Candida albicans* metabolism and biofilm formation by *Pseudomonas aeruginosa* phenazines. *MBio* 2013;**4**:e00526-12

Moree WJ, Phelan V V, Wu CH *et al.* Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. *Proc Natl Acad Sci U S A* 2012;**109**:13811–6.

Mowat E, Paterson S, Fothergill JL *et al.* *Pseudomonas aeruginosa* population diversity and turnover in cystic fibrosis chronic infections. *Am J Respir Crit Care Med* 2011;**183**:1674–9.

Nagano Y, Millar BC, Johnson E *et al.* Fungal infections in patients with cystic fibrosis. *Rev Med Microbiol* 2007;**18**.

Nevalainen TJ, Graham GG, Scott KF. Antibacterial actions of secreted phospholipases A2. *Biochim. Biophys. Acta.* 2008. **1781,** 1-9.

Nguyen D, Singh PK. Evolving stealth: genetic adaptation of *Pseudomonas aeruginosa* during cystic fibrosis infections. *Proc Natl Acad Sci U S A* 2006;**103**:8305–6.

Norman RS, Moeller P, McDonald TJ *et al.* Effect of pyocyanin on a crude-oil-degrading microbial community. *Appl Environ Microbiol* 2004;**70**:4004–11.

Nwugo CC, Arivett BA, Zimbler DL *et al.* Effect of Ethanol on Differential Protein Production and Expression of Potential Virulence Functions in the Opportunistic Pathogen *Acinetobacter baumannii*. *PLoS One* 2012;**7**: e51936.

O’Brien S, Rodrigues AMM, Buckling A. The evolution of bacterial mutation rates under simultaneous selection by interspecific and social parasitism. *Proc Biol Sci* 2013;**280**:20131913.

O’Brien S, Williams D, Fothergill JL *et al.* High virulence sub-populations in *Pseudomonas aeruginosa* long-term cystic fibrosis airway infections. *BMC Microbiol* 2017;**17**:30.

O'Malley YQ, Abdalla MY, McCormick ML, *et al*. Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2003;284:L420–L430.

O’May CY, Sanderson K, Roddam LF *et al.* Iron-binding compounds impair *Pseudomonas aeruginosa* biofilm formation, especially under anaerobic conditions. *J Med Microbiol* 2009;**58**:765–73.

Palmer KL, Mashburn LM, Singh PK *et al.* Cystic fibrosis sputum supports growth and cues key aspects of *Pseudomonas aeruginosa* physiology. *J Bacteriol* 2005;**187**:5267–77.

Peters BM, Jabra-Rizk MA, O’May GA *et al.* Polymicrobial interactions: Impact on pathogenesis and human disease. *Clin Microbiol Rev* 2012;**25**:193–213.

Pernet E, Guillemot L, Burgel P-R *et al.* *Pseudomonas aeruginosa* eradicates *Staphylococcus aureus* by manipulating the host immunity. *Nat Commun* 2014;**5**:5105.

Pihet M, Carrere J, Cimon B *et al.* Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis--a review. *Med Mycol* 2009;**47**:387–97.

Prakash Gnanadhas D, Elango M, Janardhanraj S *et al.* Successful treatment of biofilm infections using shock waves combined with antibiotic therapy. *Nat Publ Gr* 2015:1–12.

Pressler T, Bohmova C, Conway S *et al.* Chronic *Pseudomonas aeruginosa* infection definition: EuroCareCF Working Group report. *J Cyst Fibros* 2011;**10:**S75-8.

Qu XD, Lehrer RI. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. *Infect. Immun.* 1998.**66**, 2791–2797

Ramsey DM, Wozniak DJ. Understanding the control of *Pseudomonas aeruginosa* alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. *Mol Microbiol* 2005;**56**:309–22.

Rea MC, Alemayehu D, Paul Ross R *et al.* Gut solutions to a gut problem: Bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. *J Med Microbiol* 2013;**62**:1369–78.

Reece E, Segurado R, Jackson A *et al.* Co-colonisation with *Aspergillus fumigatus* and *Pseudomonas aeruginosa* is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. *BMC Pulm Med* 2017;**17**:70.

Riedel K, Hentzer M, Geisenberger O *et al.* N-acylhomoserine-lactone-mediated communication between *Pseudomonas aeruginosa* and *Burkholderia cepacia* in mixed biofilms. *Microbiology* 2001;**147**:3249–62.

Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. *J Intern Med* 2012;**272**:541–61.

Sahand IH, Moragues MD, Robert R *et al.* Evaluation of Bichro-Dubli Fumouze to distinguish *Candida dubliniensis* from *Candida albicans*. *Diagn Microbiol Infect Dis* 2006;**55**:165–7.

Sajjan U, Thanassoulis G, Cherapanov V *et al.* Enhanced Susceptibility to Pulmonary Infection with *Burkholderia cepacia* in Cftr(−/−) Mice. Tuomanen EI (ed.). *Infect Immun* 2001;**69**:5138–50.

Scanlan PD, Buckling A. Co-evolution with lytic phage selects for the mucoid phenotype of *Pseudomonas fluorescens* SBW25. *ISME J* 2012;**6**:1148–58.

Schwab U, Abdullah LH, Perlmutt OS *et al.* Localization of *Burkholderia cepacia* complex bacteria in cystic fibrosis lungs and interactions with *Pseudomonas aeruginosa* in hypoxic mucus. *Infect Immun* 2014;**82**:4729–45.

Shoseyov D, Brownlee KG, Conway SP *et al*. *Aspergillus* bronchitis in cystic fibrosis. *Chest*, 2006. **130** :222-226.

Singh PK, Parsek MR, Greenberg EP *et al.* A component of innate immunity prevents bacterial biofilm development. *Nature* 2002;**417**:552–5.

Smith EE, Buckley DG, Wu Z *et al.* Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. *Proc Natl Acad Sci U S A* 2006;**103**:8487–92.

Sorensen RU, Klinger JD. Biological effects of *Pseudomonas aeruginosa* phenazine pigments. *Antibiot Chemother* 1987;**39**:113–24.

Sousa AM, Pereira MO. *Pseudomonas aeruginosa* Diversification during Infection Development in Cystic Fibrosis Lungs—A Review. *Pathogens* 2014;**3**:680–703.

Tognon M, Kohler T, Gdaniec BG *et al.* Co-evolution with *Staphylococcus aureus* leads to lipopolysaccharide alterations in *Pseudomonas aeruginosa*. *ISME J* 2017. doi: 10.1038/ismej.2017.83

Tyrrell J, Callaghan M. Iron acquisition in the Cystic Fibrosis lung and potential for novel therapeutic strategies. *Microbiology* 2015:191–205.

Valenza G, Tappe D, Turnwald D *et al.* Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. *J Cyst Fibros* 2008;**7**:123–7.

Wang Y, Wilks JC, Danhorn T *et al.* Phenazine-1-carboxylic acid promotes bacterial biofilm development via ferrous iron acquisition. *J Bacteriol* 2011;**193**:3606–17.

Waters EM, Neill DR, Kaman B *et al.* Phage therapy is highly effective against chronic lung infections with *Pseudomonas aeruginosa*; *Thorax* 2017.

Weaver VB, Kolter R. *Burkholderia spp*. Alter *Pseudomonas aeruginosa* Physiology through Iron Sequestration. *J Bacteriol* 2004;**186**:2376–84.

West SA, Diggle SP, Buckling A *et al.* The Social Lives of Microbes. *Annu Rev Ecol Evol Syst* 2007;**38**:53–77.

Whelan FJ, Heirali AA, Rossi L *et al.* Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis. *PLoS One* 2017;**12**:e0172811.

Whiley RA, Sheikh NP, Mushtaq N *et al.* Differential potentiation of the virulence of the *Pseudomonas aeruginosa* cystic fibrosis liverpool epidemic strain by oral commensal streptococci. *J Infect Dis* 2014;**209**:769–80.

Winstanley C, Fothergill JL. The role of quorum sensing in chronic cystic fibrosis *Pseudomonas aeruginosa* infections. *FEMS Microbiol Lett* 2009;**290**:1–9.

Winstanley C, O’Brien S, Brockhurst MA. *Pseudomonas aeruginosa* Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections. *Trends Microbiol* 2016;**24**:327–37.

Wolter DJ, Emerson JC, McNamara S *et al.* *Staphylococcus aureus* small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. *Clin Infect Dis* 2013;**57**:384–91.

Wolter JM, Kotsiou G, McCormack JG. Mixed morphotype testing of *Pseudomonas aeruginosa* cultures from cystic fibrosis patients. *J Med Microbiol* 1995;**42**:220–4.

Yao GW, Duarte I, Le TT *et al.* A Broad Host Range Tailocin from *Burkholderia cenocepacia*. *Appl Environ Microbiol* 2017;pii:AEM.03414-16.